Kornimate/medical-research-clean huggingface dataset:
fixation for the treatment of femoral neck fractures

Conditions: Femoral Neck Fracture

Summary: the femoral neck fracture is the most prevalent injuries which commonly encountered among older people with high mortality, morbidity and young fit healthy ones who subjected to high-energy trauma . non-union or avascular necrosis of femoral neck fracture which lead to loss of labor capacity and death, is the most commonly occurred complication and results in considerable burden for family. the treatment is difficult and challenging, and to minimize the negative results such as limited mobilization or other complications, it is essential to take active prevention and appropriate treatment depending on fracture pattern and patients' characteristics as early as possible. however, current implant selections for femoral neck fractures remain a topic of greater interest and controversy, and vary substantially from each other .

the incidence of femoral neck fracture accounts for 3.6% of all fractures, is the most prevalent injuries which commonly encountered among older people with high mortality, morbidity and young fit healthy ones who subjected to high-energy trauma . non-union or avascular necrosis of femoral neck fracture which lead to loss of labor capacity and death, is the most commonly occurred complication and results in considerable burden for family. the treatment is difficult and challenging, and to minimize the negative results such as limited mobilization or other complications, it is essential to take active prevention and appropriate treatment depending on fracture pattern and patients' characteristics as early as possible. however, current implant selections for femoral neck fractures remain a topic of greater interest and controversy, and vary substantially from each other depending on the extent of displacement, fracture configuration, physiological age of the patient, bone quality or other relative factors. nonoperative management is considered only when patients are seriously ill or presented with excessive surgical risk.

Eligibility criteria:
inclusion criteria: * closed femoral neck fracture * no fractures at other sites * surgical treatment with cannulated compression screws or pfna * follow-up time greater than 1 years. exclusion criteria: * the absence of severe cognitive dysfunction, * the presence of a pathological femoral neck fracture * previous femoral neck fracture, treated with other internal fixations and surgical treatment with open reduction.
meso-car t cells therapy for relapsed and refractory epithelial ovarian cancer

Conditions: Ovarian Cancer

Summary: the goal of this clinical trial is to study the feasibility and efficacy of anti-meso antigen receptors (cars) t cell therapy for relapsed and refractory epithelial ovarian cancer.

primary objectives to determine the feasibility ad safety of anti-meso car-t cells in treating patients with meso-positive ovarian cancer. secondary objectives to access the efficacy of anti-meso car-t cells in patients with ovarian cancer. to determine in vivo dynamics and persistency of anti- meso car-t cells.

Eligibility criteria:
inclusion criteria: - 18 to 70 years old, female; expected survival \> 12 weeks; clinical performance status of ecog score 0-2; patients who have previously been treated with second- line or more lines of standard treatment are not effective (no remission or recurrence after remission); at least one measurable tumor foci according to recist standard 1.1 ; positive mesothelin expression in tumor tissues; creatinine ≤ 1.5×uln; alt and ast ≤ 3×uln; total bilirubin ≤ 2×uln; hemoglobin≥90g/l; absolute counting of neutrophils≥1000ul ; absolute counting of lymphocytes\>0.7×10\^9/l; counting of platelet≥75000/ul; the venous access required for collection can be established without contraindications for leukocyte collection; able to understand and sign the informed consent document. exclusion criteria: - accompanied by other uncontrolled malignant tumors; active hepatitis b, hepatitis c, syphilis, hiv infection; suffering severe cardiovascular or respiratory disease; any other diseases could affect the outcome of this trial; any affairs could affect the safety of the subjects or outcome of this trial; pregnant or lactating women, or patients who plan to be pregnancy during or after treatment; there are active or uncontrollable infections (except simple urinary tract infections or upper respiratory tract infections) that require systemic therapy 14 days or 14 days prior to assignment; patients who are accounted by researchers to be not appropriate for this test; received car-t treatment or other gene therapies before assignment; subject suffering disease affects the understanding of informed consent or comply with study protocol.

Keywords: ovarian cancer car-t meso relapsed and refractory
stretching and musculoskeletal pain

Conditions: Musculoskeletal Pain

Summary: the purpose of this study is to assess whether a daily, 15-minute stretching routine for one year reduces musculoskeletal pain and improves quality of life in personnel working in the radiology and cardiology departments at mayo clinics and mayo clinic health system sites.


Eligibility criteria:
inclusion criteria: * a 15-minute daily stretching program will be implemented for 1 year. * personnel working in the departments of cardiology and radiology at mayo rochester, - mayo scottsdale, and mayo jacksonville and mayo clinic health system. * willing to complete standardized questionnaires (dash, odi) to assess work-related pain at baseline and at 1 year. * employees who respond to questionnaires at baseline and 1 year but don't participate in the stretching exercises will be controls for the study. * willing and able to provide written, informed consent. exclusion criteria: * pregnancy. * inability to participate in the stretching exercises for any reason. * preexisting musculoskeletal problems that has required employees to seek active medical or orthopedic treatment.
a comparative study between early onset colorectal cancer and late onset colorectal cancer patients

Conditions: Colorectal Cancer

Summary: this study aims to investigate the clinical, socioeconomic, behavioral, genetic, and molecular factors characterizing early onset colorectal cancer (eocrc) patients compared with late onset colorectal cancer (locrc) patients

early onset colorectal cancer (eocrc), defined as a colorectal cancer (crc) arising before the age of 50, is increasing and displays more aggressive features compared with late onset colorectal cancer (locrc, with a diagnosis after the age of 50). eocrc patients have indeed a higher incidence rate of crc recurrence after surgery compared with locrc, even at early crc stages (stage i or ii). the reasons underlying the more aggressive patterns are almost unknown but may span and can be represented by a combination of socioeconomic factors (including low economic income and access to screening programs, diagnosis, or therapy), behavioral and lifestyle factors (including diet, sedentary behaviors, or increased stress and anxiety), and molecular or genetic factors. the aim of this study is to prospectively validate our previous retrospective findings, demonstrating a higher incidence rate of crc recurrence in early stage eocrc, and explore the possible association between lifestyle, dietary, socioeconomics, molecular and genetic factors and postoperative crc survival.

Eligibility criteria:
inclusion criteria: * patients aged more than 18 years old at the time of inclusion. * patients with a proven diagnosis of colorectal adenocarcinoma, as reported by the staging histological biopsies. * patients with a preoperative staging i-iii. * patients scheduled for elective curative colorectal resection. * patients with rectal cancer who underwent neoadjuvant therapy can be included in the study. * patients able and willing to comply with the protocol requirements (samples' collection and questionnaires' compilation). exclusion criteria: * patients with metastatic disease at diagnosis. * patients requiring an emergent procedure. * patients undergoing palliative surgery (for example, fecal diversion). * patients with a surgical indication for benign lesions (for example, adenoma or dysplasia). * patients with an intraoperative finding of a lesion other than adenocarcinoma will be withdrawn from the study. * patients with an intraoperative finding of distal metastasis or peritoneal carcinosis will be withdrawn from the study. * patients with a concomitant diagnosis of inflammatory bowel disease. * patients with a known genetic syndrome (for example, lynch syndrome or familial adenomatous polyposis).

Keywords: early onset colorectal cancer cancer survival genetic and molecular characterization
study of telbivudine and lamivudine to prevent vertical transmission of hepatitis b

Conditions: Chronic Hepatitis B; Late Pregnancy; Transmission; Complication

Summary: the purpose of this study is to evaluate the efficacy and safety of telbivudine and lamivudine use during late pregnancy for the prevention of hbv perinatal transmission in highly viraemic mothers.

this study enrolls hbv mono-infected pregnant women cohorts managed in outpatient clinics/delivery unit at youan hospital in beijing. subjects are prospectively followed from gestation week 26 to postpartum week 52. treatment naïve mothers with hbv dna \> 6 log10 c/ml and normal alt are eligible. mothers with abnormal fetus, cirrhosis or evidence of hepatocellular carcinoma (hcc) are excluded. at gestation week 28, mothers will receive telbivudine (ldt) 600 mg per day or lamivudine (lam) 100 mg per day until postpartum 4 or no treatment as per their preference. all infants will receive standard immunoprophylaxis. data is collected from patient records using data extraction forms. primary endpoints are vertical transmission rates at infants' age of 52 week and the safety of telbivudine or lamivudine use.

Eligibility criteria:
inclusion criteria: 1. age: 20-40 years old 2. hbsag, hbeag positive and hbv dna \>6 log10 copies/ml 3. gestational age: 26-28 weeks with normal fetus 4. willing to consent for the study exclusion criteria: 1. elevated alt 2. antiviral treatment experience patients 3. co-infection with hav, hcv,hdv, hiv 4. concurrent treatment with immune modulators, cytotoxic drugs, or steroids 5. clinical signs of threatened miscarriage in early pregnancy 6. clinical evidence of cirrhosis and/or hepatocellular carcinoma

Keywords: telbivudine lamivudine safety efficacy pregnancy
improving employment in patients who have survived cervical cancer, uterine cancer, or ovarian cancer

Conditions: Cervical Cancer; Ovarian Cancer; Sarcoma

Summary: rationale: finding out which problems affect employment in survivors of gynecologic cancer may help in planning cancer treatment and improve the quality of life of future cancer survivors. purpose: this research study is looking at ways to improve employment in patients who have survived cervical cancer, uterine cancer, or ovarian cancer.

objectives: * conduct formative work, including 4 to 5 focus groups, leading to development of a structured interview instrument assessing factors related to employment outcomes among women with gynecologic cancers. * pilot a recruitment strategy and administer the interview among a sample of 60 to 70 gynecologic cancer survivors; and, with each woman's permission, a family member, a key health care provider, and her supervisor will be interviewed. outline: this is a multicenter, pilot study. patients complete a survey, meet with a focus group, and undergo a short interview. patient-designated participants are also interviewed; these individuals may include a health care provider, a significant other, and/or a work supervisor. projected accrual: a total of 70 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of 1 of the following invasive cancers: * cervical cancer * uterine cancer * ovarian cancer * diagnosed ≥ 6 months ago * any stage disease * employed at the time of diagnosis, defined as working for pay ≥ 20 hours/week patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: recurrent cervical cancer stage 0 cervical cancer stage ia cervical cancer stage ib cervical cancer stage iia cervical cancer stage iib cervical cancer stage iii cervical cancer stage iva cervical cancer stage ivb cervical cancer recurrent uterine sarcoma stage i uterine sarcoma stage ii uterine sarcoma stage iii uterine sarcoma stage iv uterine sarcoma borderline ovarian surface epithelial-stromal tumor ovarian sarcoma ovarian stromal cancer recurrent ovarian epithelial cancer recurrent ovarian germ cell tumor stage i ovarian epithelial cancer stage i ovarian germ cell tumor stage ii ovarian epithelial cancer stage ii ovarian germ cell tumor stage iii ovarian epithelial cancer stage iii ovarian germ cell tumor stage iv ovarian epithelial cancer stage iv ovarian germ cell tumor
center of research translation (cort) project 2

Conditions: Pre-hypertension; JNC 7 Stage I Hypertension

Summary: we propose a novel intervention for reducing bp that could have a preferential impact in patients with hyperuricemia and gout. there is a great need for new anti-hypertensives, particularly among those with gout. the proposed study is novel in its plans to investigate the physiologic mechanisms through which urate contributes to vascular disease and by which ult may contribute to bp reduction. also innovative, we will: 1) determine to what extent the described benefit of lowering serum urate extends beyond the adolescent population previously studied into young adults, 2) test whether a urate-lowering approach will benefit individuals that do not yet meet the current definition of hyperuricemia and do not have gout, and 3) begin to explore potential mechanisms for the higher prevalence of hypertension among african-americans. if successful, this work could translate to the standard of clinical care and to health care recommendations for the population as a whole.


Eligibility criteria:
inclusion criteria: * pre-hypertension or stage i hypertension, defined as the following after the mean of two clinic measurements: * systolic blood pressure (sbp) ≥ 120 and \<160 or; * diastolic blood pressure (dbp) ≥ 80 and \< 100 * serum urate ≥ 5.0 mg/dl for men or ≥ 4.0 mg/dl for women * age 18-40 exclusion criteria: * any current pharmacological treatment for hypertension, including diuretics (calcium channel blockers at stable doses were later allowed) * estimated glomerular filtration rate \< 60 ml/min/1.73m2 * current use of any urate-lowering therapy or statins * prior diagnosis of gout or past use of urate-lowering therapy for gout * prior diagnosis of diabetes * pregnancy, or recent delivery or last trimester pregnancy loss more recent than 3 months * active smokers * immune-suppressed individuals including transplant recipients or current use of azathioprine. * leucopenia with absolute white cell count \< 3000 /ml, anemia with hemoglobin \< 12 g/dl, or thrombocytopenia with platelet count \< 150,000/ml * individuals of han chinese or thai descent with hlab5801 genetic phenotype * serious medical condition that at investigator's judgment precludes utilization of a fixed dose of allopurinol

Keywords: pre-hypertension jnc 7 stage i hypertension
combined microbiota and metabolic signature in ulcerative colitis predicts anti-inflammatory therapy success

Conditions: Ulcerative Colitis

Summary: the primary goal of the study is to develop an early (within 4 weeks) combined microbiota/metabolic signature predicting clinical response upon anti-inflammatory treatment in uc patients.

the investigators perform a longitudinal prospective multi-center study for ulcerative colitis (uc) patients with a flare at/and after the time of starting a new treatment and healthy household controls. they will perform intense longitudinal bio-sampling and deep clinical characterization. with this information the aim is to develop a predictive signature regarding the success of a new ly started anti-inflammatory therapy after an uc flare.

Eligibility criteria:
inclusion criteria ulcerative colitis: 1. signed informed consent 2. age 18-80 years 3. general ability to understand and follow study procedures, fluency in german, french, or english 4. diagnosis of ulcerative colitis since ≥3 months 5. confirmed flare of ulcerative colitis with partial sccai score ≥5 points and at least one biomarker supporting intestinal inflammation 6. planned start with ozanimod, steroids (prednisone ≥20mg/d or equivalent), or a biological (vedolizumab, infliximab, adalimumab, golimumab, ustekinumab) exclusion criteria ulcerative colitis 1. confirmed cytomegalovirus (cmv) reactivation within the previous 2 weeks (tested as part of standard medical practice at the discretion of the responsible physician) 2. c. difficile related diarrhea, or other confirmed infectious diarrhea in the last 4 weeks (tested as part of standard medical practice at the discretion of the responsible physician) 3. diagnosis of crohn's disease 4. current pouch or ileostomy/ colostomy 5. severe medical, surgical, or psychiatric comorbidities interfering with study procedures inclusion criteria controls 1. signed informed consent 2. age 18-80 years 3. general ability to understand and follow study procedures, fluency in german, french, or english 4. no current or past diagnosis of inflammatory bowel disease (ibd) 5. no current medical complaints typic for ibd e.g. * diarrhea, severe constipation, abdominal pain, blood in stool, weight loss * slight symptoms (without impact onto daily activities) are permitted 6. no other current relevant gastrointestinal disease or condition plausibly interfering with microbiota assessment according to the discretion of the study physician exclusion criteria controls 1. confirmed cytomegalovirus (cmv) reactivation within the previous 2 weeks 2. c. difficile related diarrhea, or other confirmed infectious diarrhea in the last 4 weeks 3. diagnosis of crohn's disease, ulcerative colitis 4. current pouch or ileostomy/ colostomy 5. severe medical, surgical, or psychiatric comorbidities interfering with study procedures
no routine cxr after bronchoscopy

Conditions: Pneumothorax

Summary: most pulmonologist request a routine chest-x-ray after bronchoscopy with transbronchial biopasie to exclude pneumothorax. we published a study in chest showing that routine chest-ray might not be necessary. we would like to conduct a propsective study to validate the results of the chest-study. before and after the procedure follwing information will be collected: age, sex, indication for procedure, number of biopsies and segment of biopsie, saturation, physical examination, symptoms suggestive of pneumothorax. if there is no aggravation of the symptoms and/or physical examination after the procedure, as compared to before, routine chest-x-ray will not be done. a phone will be made 24 to 48 hours following the procedure to the patient.


Eligibility criteria:
inclusion criteria: * all patients with bronchoscopy and transbronchial biopsie exclusion criteria: * no informed consent given
effect of laparoscopic ovarian drilling on outcomes of in vitro fertilisation in clomiphene-resistant women with polycystic ovary syndrome

Conditions: PCOS

Summary: the polycystic ovarian syndrome is associated with an ovulation and infertility. recently the laparoscopic ovarian drilling has been used as surgical treatment for ovulation in women with polycystic ovarian syndrome, although its mechanism and outcomes are still unclear. this study is undertaken to evaluate the in vitro fertilisation outcomes in clomiphene-resistant women with pcos who were treated with lod.


Eligibility criteria:
inclusion criteria: * age between 25 and 35 * patients with established pcos * history at least one year infertility * no response to clomiphene citrate for at least three cycles exclusion criteria: * history of previous ivf/icsi * chronic disease such as thyroid disorder and dm * infertility due to sever male factor * sever endometriosis * infertility due to uterine factor such as multiple fibroid * body mass index \> 30
pain relief during repair of postpartum perineal tears

Conditions: Improving Quality of Life

Summary: the aim of our study is to compare the analgesic effect of topical application of lidocaine-prilocaine cream and lidocaine infiltration during repair of postpartum perineal tears.


Eligibility criteria:
inclusion criteria: 1. gestational age \> 37 weeks 2. uncomplicated pregnancy 3. single vertex fetus 4. normal vaginal delivery 5. women who will accept to participate in the study exclusion criteria: 1. women received epidural analgesia 2. women required episiotomy 3. women with intact perineum 4. operative vaginal delivery 5. allergy to the used drugs
anidulafungin plus voriconazole versus voriconazole for the treatment of invasive aspergillosis

Conditions: Aspergillosis

Summary: this study compares the effectiveness and safety of the combination of anidulafungin and voriconazole compared to that of voriconazole alone (which is generally considered the standard of care) for the treatment of invasive aspergillosis.


Eligibility criteria:
inclusion criteria: * immunocompromised state due to either 1. receipt of hematopoeitic stem cell transplantation or 2. hematologic malignancy; * diagnosis of possible, probable, or proven invasive aspergillosis. exclusion criteria: * patients with aspergilloma or chronic aspergillosis * receipt of 4 or more days of systemic antifungal treatment for the current episode of invasive aspergillosis * anticipated survival of less than 5 days or karnofsky score \<=20
evaluation of the use of a biodegradable endoprothesis in the prevention of post-endoscopic retrograde choloangiopancreatography pancreatitis

Conditions: Obstructive Jaundice; Biliary Stricture; Sphincter of Oddi Dysfunction

Summary: the use of an endoprothesis in a pancreatic duct is a measure to minimize the incidence and severity of post-endoscopic retrograde choloangiopancreatography pancreatitis. in this study we will evaluate the use of a biodegradable endoprothesis: archimede fast biodegradable pancreatic stent in patients with high risk of post-endoscopic retrograde choloangiopancreatography pancreatitis.the archimedes fast biodegradable pancreatic stent will be placed during the endoscopic retrograde choloangiopancreatography. the efficacy and the security of the device will be evaluated.


Eligibility criteria:
inclusion criteria: * age\>18 years * patients at risk of developing a post-endoscopic retrograde choloangiopancreatography pancreatitis (procedure and/or patient-related risk factors exclusion criteria: * pregnant or breastfeeding women * recent diagnosis (\<1 month) of acute pancreatitis * contraindication to endoscopy * hypersensitivity to indomethacine

Keywords: biodegradable stent post-endoscopic retrograde choloangiopancreatography pancreatitis